Status:
NOT_YET_RECRUITING
Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia
Lead Sponsor:
Baylor College of Medicine
Conditions:
Central Centrifugal Cicatricial Alopecia
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
This study aims to investigate whether platelet-rich plasma (PRP) injections can help treat central centrifugal cicatricial alopecia (CCCA), a type of scarring hair loss that mostly affects women of A...
Detailed Description
Central centrifugal cicatricial alopecia (CCCA) is a common form of permanent hair loss that primarily affects Black women, with up to 20% of this population experiencing the condition. CCCA is charac...
Eligibility Criteria
Inclusion
- Female
- Minimum age of 18 years old
- Self-identification as person of African descent, including African, Afro-Caribbean, Afro-Latino, and/or African American
- Clinical diagnosis of mild to moderate CCCA located on the vertex or fronto-vertex scalp, and as defined by Central Hair Loss Grade stages 1B, 2B, and 3B
Exclusion
- Intralesional or systemic anti-inflammatory medications (corticosteroids, tetracycline antibiotics, anti-malarials) or immunosuppressive drugs (cyclosporine, mycophenolate mofetil, methotrexate, azathioprine, janus kinase inhibitors) within 4 weeks of baseline visit
- Pregnant women
- Topical minoxidil, metformin, or retinoic acid for 4 weeks prior to baseline visit
- Severe or end-stage CCCA, Central Hair Loss Grade stage \>3B
- Thrombocytopenia (as defined by baseline platelet count \< 150,000 platelets per microliter of blood)
- Antiplatelet or platelet altering medications (such as but not limited to aspirin, NSAIDS, clopidogrel, ticagrelor, and prasugrel, cilostazol, and dipyridamole) within 4 weeks of baseline visit
- Diagnosis of other significant concomitant alopecia
- Clinically significant uncontrolled disease, malignancy, or major psychiatric illness requiring hospitalization (as determined by investigator)
- Subjects not willing to follow suggested hair care practices such as limiting/avoiding traction-associated styles
Key Trial Info
Start Date :
September 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2026
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT06998433
Start Date
September 30 2025
End Date
July 31 2026
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jamail Specialty Care Center
Houston, Texas, United States, 77030